Is CytomX Therapeutics, Inc. overvalued or undervalued?

As of 12 May 2025, the valuation grade for CytomX Therapeutics, Inc. moved from risky to attractive, indicating a significant improvement in its financial outlook. The company is currently considered undervalued, supported by a P/E ratio of 10, a PEG ratio of 0.14, and an EV to EBITDA ratio of 9.07. These ratios suggest that the stock is trading at a lower valuation compared to its earnings growth potential.
In comparison to its peers, CytomX Therapeutics stands out with a P/E ratio of 9.01 and an EV to EBITDA of 7.98, while other companies like Chimerix, Inc. and aTyr Pharma, Inc. do not qualify for direct comparison due to negative valuations. Notably, CytomX's ROE is exceptionally high at 166.09%, further reinforcing its attractiveness despite the recent stock performance, which has seen a year-to-date return of 109.71%, significantly outperforming the S&P 500's 2.44%.